Carlos A Zarate

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint A double-blind, placebo-controlled study of memantine in the treatment of major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA
    Am J Psychiatry 163:153-5. 2006
  2. pmc A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Biol Psychiatry 74:257-64. 2013
  3. pmc Human biomarkers of rapid antidepressant effects
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 73:1142-55. 2013
  4. pmc Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Psychiatry 72:331-8. 2012
  5. pmc Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 71:939-46. 2012
  6. pmc The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Exp Neurol 211:7-10. 2008
  7. pmc Riluzole in psychiatry: a systematic review of the literature
    Carlos A Zarate
    Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
    Expert Opin Drug Metab Toxicol 4:1223-34. 2008
  8. pmc Glutamatergic modulators: the future of treating mood disorders?
    Carlos Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Harv Rev Psychiatry 18:293-303. 2010
  9. ncbi request reprint Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 9:561-70. 2007
  10. pmc Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Bethesda, Maryland, USA
    CNS Drugs 23:569-82. 2009

Collaborators

Detail Information

Publications96

  1. ncbi request reprint A double-blind, placebo-controlled study of memantine in the treatment of major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA
    Am J Psychiatry 163:153-5. 2006
    ..This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans...
  2. pmc A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Biol Psychiatry 74:257-64. 2013
    ..This study investigated whether AZD6765 could produce rapid antidepressant effects in subjects with treatment-resistant major depressive disorder (MDD)...
  3. pmc Human biomarkers of rapid antidepressant effects
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 73:1142-55. 2013
    ..g., ketamine or scopolamine). This alternative translational model for new treatments in psychiatry would facilitate shorter studies, improve feasibility, and increase higher compound throughput testing for these devastating disorders...
  4. pmc Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Biol Psychiatry 72:331-8. 2012
    ..Ketamine is extensively metabolized. This study examined the relationship between ketamine metabolites and response, diagnosis, and psychotomimetic symptoms in MDD and BD patients...
  5. pmc Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial
    Carlos A Zarate
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 71:939-46. 2012
    ..The present study sought to replicate this finding in an independent sample...
  6. pmc The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Exp Neurol 211:7-10. 2008
  7. pmc Riluzole in psychiatry: a systematic review of the literature
    Carlos A Zarate
    Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
    Expert Opin Drug Metab Toxicol 4:1223-34. 2008
    ..Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent...
  8. pmc Glutamatergic modulators: the future of treating mood disorders?
    Carlos Zarate
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Harv Rev Psychiatry 18:293-303. 2010
    ..Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder...
  9. ncbi request reprint Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 9:561-70. 2007
    ..In this study, we investigated whether antimanic effects can be achieved with a protein kinase C inhibitor in subjects with mania...
  10. pmc Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorder
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Bethesda, Maryland, USA
    CNS Drugs 23:569-82. 2009
    ..The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness...
  11. ncbi request reprint Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 59:1006-20. 2006
    ....
  12. ncbi request reprint An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 57:430-2. 2005
    ..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression...
  13. ncbi request reprint A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
    Carlos A Zarate
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    Arch Gen Psychiatry 63:856-64. 2006
    ..Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders...
  14. ncbi request reprint Pramipexole for bipolar II depression: a placebo-controlled proof of concept study
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institute of Health, Department of Human and Health Services, Bethesda, Maryland, USA
    Biol Psychiatry 56:54-60. 2004
    ..The current study was undertaken as a proof of the concept that dopamine agonists will be effective in patients with bipolar II depression...
  15. ncbi request reprint Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    Ann N Y Acad Sci 1003:273-91. 2003
    ....
  16. pmc Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, Laboratory of Molecular Psychiatry and Experimental Therapeutics, National Institute of Mental Health NIMH, National Institutes of Health NIH, Department of Health and Human Services, Bethesda, Maryland, USA
    J Clin Psychiatry 70:1662-6. 2009
    ..This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of ketamine, a high-affinity N-methyl-D-aspartate (NMDA) antagonist...
  17. pmc Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 35:1415-22. 2010
    ..73, p=0.0021, FDR <0.05).These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context...
  18. pmc Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression
    David A Luckenbaugh
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 14:880-7. 2012
    ..This study investigated whether FHP influences ketamine's antidepressant and perceptual effects in individuals with bipolar depression...
  19. pmc A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
    Nancy Diazgranados
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Arch Gen Psychiatry 67:793-802. 2010
    ..Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health...
  20. pmc Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study
    Jonathan B Savitz
    Mood and Anxiety Disorders Program, National Institutes of Health National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 69:336-43. 2011
    ..We conducted the first magnetic resonance imaging analysis of habenula volume in MDD and bipolar disorder (BD)...
  21. pmc Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression
    Brian R Cornwell
    Section on Neurobiology of Fear and Anxiety, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    Biol Psychiatry 72:555-61. 2012
    ..Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine...
  22. pmc Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD, USA
    Neuropsychopharmacology 37:1526-33. 2012
    ....
  23. pmc A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression
    M Kathleen Holmes
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Bipolar Disord 10:806-15. 2008
    ..The present study aims to compare the cognitive performance of medicated and unmedicated subjects with bipolar depression to healthy control subjects...
  24. pmc Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder
    Nancy Diazgranados
    National Institute of Mental Health, and Department of Human Health Services, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1605-11. 2010
    ..We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD)...
  25. pmc An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression
    Giacomo Salvadore
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 15:1063-72. 2012
    ....
  26. pmc Abnormal hippocampal functioning and impaired spatial navigation in depressed individuals: evidence from whole-head magnetoencephalography
    Brian R Cornwell
    Mood and Anxiety Disorders Program, NIMH, 15K North Dr, MSC 2670, Bethesda, MD 20892, USA
    Am J Psychiatry 167:836-44. 2010
    ..The authors aimed to link spatial navigation deficits previously documented in depressed patients to abnormal hippocampal functioning using a virtual reality navigation task...
  27. pmc Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
    Wallace C Duncan
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 16:301-11. 2013
    ..Further studies are required to confirm the link found here between behavioural and synaptic changes, as well as to test the reliability of these central and peripheral biomarkers of rapid antidepressant response...
  28. pmc Early intervention in bipolar disorder, part II: therapeutics
    Giacomo Salvadore
    Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Early Interv Psychiatry 2:136-46. 2008
    ..We also discuss their potential use as early intervention strategies for improving symptoms and functioning in patients in the earliest stages of BPD, as well as high-risk individuals...
  29. pmc Ketamine and the next generation of antidepressants with a rapid onset of action
    Rodrigo Machado-Vieira
    Experimental Therapeutics Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Pharmacol Ther 123:143-50. 2009
    ..Overall, understanding the molecular basis of this work will likely lead to the ultimate development of improved therapeutics for MDD...
  30. pmc Early improvement with lithium in classic mania and its association with later response
    Rodrigo Machado-Vieira
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA
    J Affect Disord 144:160-4. 2013
    ..This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania...
  31. pmc Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Neuroimage 63:1532-41. 2012
    ....
  32. ncbi request reprint Regional cerebral glucose metabolic abnormalities in bipolar II depression
    Linda Mah
    Section on Neuroimaging in Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    Biol Psychiatry 61:765-75. 2007
    ..This study investigated whether cerebral metabolic abnormalities previously reported in unmedicated BD subjects are evident in depressed bipolar disorder type II (BD II) subjects receiving lithium or divalproex...
  33. pmc A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder
    Judah D Weathers
    Section on Bipolar Spectrum Disorders, Emotion and Development Branch, NIMH, Bethesda, MD, USA
    Am J Psychiatry 169:633-41. 2012
    ..The authors compared the neural circuitry mediating this process in bipolar youths relative to bipolar adults and in healthy volunteers...
  34. ncbi request reprint An open-label trial of riluzole in patients with treatment-resistant major depression
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
    Am J Psychiatry 161:171-4. 2004
    ..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression...
  35. pmc Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder
    Wallace C Duncan
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    J Affect Disord 145:115-9. 2013
    ..This study examined the relationship between baseline patterns of SWA in the first two NREM episodes and antidepressant response to an acute infusion of the N-methyl-d-aspartate (NMDA) antagonist ketamine...
  36. pmc Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
    Biol Psychiatry 65:289-95. 2009
    ..We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation observed in healthy subjects...
  37. pmc Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist
    Laura E Phelps
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health DHHS, 10 Center Drive, Bethesda, MD 20892 1282, USA
    Biol Psychiatry 65:181-4. 2009
    ..This study investigated whether a family history of alcohol dependence influences ketamine's initial antidepressant effect...
  38. ncbi request reprint Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
    Sungho Maeng
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Biol Psychiatry 63:349-52. 2008
    ..Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action...
  39. pmc Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, MD 20892, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:1155-9. 2011
    ..However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT)...
  40. pmc Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
    Biol Psychiatry 66:804-7. 2009
    ..We tested the hypothesis that this SNP would modulate gray matter (GM) volume in the limbic-cortical-striatal-pallidal-thalamic circuitry that plays major roles in mood regulation...
  41. pmc The neurobiology of the switch process in bipolar disorder: a review
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    J Clin Psychiatry 71:1488-501. 2010
    ..In this review, we summarize the clinical evidence regarding somatic interventions associated with switching, with a particular focus on the biologic underpinnings presumably involved in the switch process...
  42. pmc A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder
    Nancy Diazgranados
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, 10 Center Drive, CRC, Unit 7 Southeast, Room 7 3445, Bethesda, MD 20892, USA
    Curr Psychiatry Rep 10:510-9. 2008
    ..We conclude that PKC is an important target-arguably the first mechanistically distinct drug target for bipolar disorder. PKC holds considerable promise as a novel target for developing a new line of treatments for bipolar disorder...
  43. pmc Baseline mood-state measures as predictors of antidepressant response to scopolamine
    Maura L Furey
    Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD 20892, USA
    Psychiatry Res 196:62-7. 2012
    ..These results indicate that self-report mood-ratings obtained before treatment can predict response outcome to scopolamine, and suggest that a constellation of mood-state features may be related to clinical response...
  44. pmc A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Psychopharmacol 32:551-7. 2012
    ..Further studies with larger sample sizes are necessary to confirm these preliminary findings...
  45. pmc Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study
    Lobna Ibrahim
    Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States
    Brain Res Bull 86:129-33. 2011
    ..These results suggest that SD is associated with mood-related changes in plasma VEGF levels, but not plasma BDNF levels. Further studies using larger sample sizes are needed to confirm these preliminary findings...
  46. pmc The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Department of Health and Human Services, Bethesda, MD 20892, USA
    Bipolar Disord 11:92-109. 2009
    ..Continued work to decipher lithium's molecular actions will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses...
  47. pmc The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorder
    Rodrigo Machado-Vieira
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
    Biol Psychiatry 69:344-52. 2011
    ..Here, we examined the effects of the Bcl-2 gene single nucleotide polymorphism (SNP) rs956572 on intracellular Ca(2+) dynamics in patients with BPD...
  48. pmc Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets
    Paul J Carlson
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892, USA
    NeuroRx 3:22-41. 2006
    ....
  49. ncbi request reprint Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression
    Husseini K Manji
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 4405, USA
    Biol Psychiatry 53:707-42. 2003
    ..The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders...
  50. pmc Perception of facial emotion in adults with bipolar or unipolar depression and controls
    Kathryn L Schaefer
    Department of Counseling and Personnel Services, University of Maryland, College Park, MD, USA
    J Psychiatr Res 44:1229-35. 2010
    ..Groups were compared in terms of sensitivity and accuracy in identifying emotions. Our preliminary findings suggest that subjects with bipolar depression may have emotional processing abnormalities relative to controls...
  51. pmc Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Pharm Des 15:1595-611. 2009
    ..This paper reviews the currently available knowledge regarding the role of the glutamatergic system in the etiopathogenesis of mood disorders and putative glutamate modulators...
  52. ncbi request reprint Performance on a virtual reality spatial memory navigation task in depressed patients
    Neda F Gould
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Mark O Hatfield Clinical Research Center, 10 Center Dr, Bethesda, MD 20892, USA
    Am J Psychiatry 164:516-9. 2007
    ..Findings on spatial memory in depression have been inconsistent. A navigation task based on virtual reality may provide a more sensitive and consistent measure of the hippocampal-related spatial memory deficits associated with depression...
  53. pmc Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder
    Maura L Furey
    Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    JAMA Psychiatry 70:280-90. 2013
    ..Scopolamine produces rapid antidepressant effects and thus offers the opportunity to characterize potential biomarkers of treatment response within short periods...
  54. pmc Acute D-serine treatment produces antidepressant-like effects in rodents
    Oz Malkesman
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Int J Neuropsychopharmacol 15:1135-48. 2012
    ..It is unclear whether D-serine has a convergent influence on downstream synaptic plasticity cascades that may yield a similar therapeutic profile to NMDA antagonists like ketamine...
  55. ncbi request reprint The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders
    Jing Du
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 32:793-802. 2007
    ....
  56. pmc Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder
    Rodrigo Machado-Vieira
    Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, MD 20892 1282, USA
    J Clin Psychiatry 69:946-58. 2008
    ..This article reviews the published data related to different aspects of rapid improvement of depressive symptoms...
  57. pmc The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Bethesda, Maryland 20892, USA
    Neuroscientist 15:525-39. 2009
    ..In therapeutically relevant paradigms, ketamine preferentially targets postsynaptic AMPA/NMDA receptors, and riluzole preferentially targets presynaptic voltage-operated channels and glia...
  58. pmc New therapeutic targets for mood disorders
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    ScientificWorldJournal 10:713-26. 2010
    ....
  59. pmc Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuroimage 54:2643-51. 2011
    ..Consistent with other neuroimaging and post-mortem neuropathological studies of MDD, we also found evidence of decreased white matter in patients with dMDD and rMDD...
  60. pmc Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode
    Giacomo Salvadore
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, Maryland, 20892 1285, USA
    Prog Neuropsychopharmacol Biol Psychiatry 34:819-21. 2010
    ..Overall, our findings suggest a novel mechanism in the pathophysiology of BPD...
  61. doi request reprint Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder
    Mark J Niciu
    1 National Institutes of Health National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, Bethesda, Maryland, USA
    CNS Spectr 18:242-51. 2013
    ..Even in the past decade, intracellular dysfunction in numerous neuroprotective/apoptotic cascades appears important in the pathophysiology and may be a future target for pharmacological interventions of BD. ..
  62. pmc Defining anxious depression: a review of the literature
    Dawn F Ionescu
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
    CNS Spectr 18:252-60. 2013
    ....
  63. pmc Combining a dopamine agonist and selective serotonin reuptake inhibitor for the treatment of depression: a double-blind, randomized pilot study
    José A Franco-Chaves
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Affect Disord 149:319-25. 2013
    ..This pilot study examined the efficacy and safety of combination therapy with pramipexole and the selective serotonin reuptake inhibitor (SSRI) escitalopram in MDD...
  64. pmc Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression
    Allison C Nugent
    1Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, USA
    J Psychopharmacol 27:894-902. 2013
    ..These preliminary findings are consistent with the hypothesis that these mood stabilizers enhance 5-HT1A receptor expression in BD, which may underscore an important component of these agents' mechanism of action. ..
  65. pmc Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions
    Rodrigo Machado-Vieira
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
    CNS Neurosci Ther 17:699-704. 2011
    ....
  66. ncbi request reprint Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder
    Kristine Erickson
    Mood and Anxiety Disorders Program, National Institute of Mental Health, MD 20814 9692, USA
    Am J Psychiatry 162:2171-3. 2005
    ..This study investigated performance of unmedicated depressed patients on the Affective Go/No-Go Task...
  67. pmc Reduced post-synaptic serotonin type 1A receptor binding in bipolar depression
    Allison C Nugent
    National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD 20892 1030, USA
    Eur Neuropsychopharmacol 23:822-9. 2013
    ..These findings suggest that 5-HT(1A) receptor binding is abnormally reduced in BD, and this abnormality may particularly involve the postsynaptic 5-HT(1A) receptor system of individuals with a tendency toward cortisol hypersecretion...
  68. pmc Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date
    Daniel C Mathews
    Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Drugs 72:1313-33. 2012
    ..There is extant evidence that the glutamatergic system holds considerable promise for developing the next generation of novel and mechanistically distinct agents for the treatment of MDD...
  69. pmc Effects of lithium on oxidative stress parameters in healthy subjects
    Rushaniya Khairova
    Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Mol Med Rep 5:680-2. 2012
    ..Overall, the present findings indicate a potential role for the antioxidant effects of lithium in healthy subjects, supporting its neuroprotective profile in bipolar disorder (BD) and, possibly, in neurodegenerative processes...
  70. ncbi request reprint Glycogen synthase kinase-3: a target for novel bipolar disorder treatments
    Todd D Gould
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
    J Clin Psychiatry 65:10-21. 2004
    ..We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge...
  71. pmc Early intervention in bipolar disorder, part I: clinical and imaging findings
    Giacomo Salvadore
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
    Early Interv Psychiatry 2:122-35. 2008
    ..A companion paper discusses the cellular and molecular mechanisms of action of agents with neurotrophic and neuroplastic properties, with a particular emphasis on lithium and valproate...
  72. pmc Differing amygdala responses to facial expressions in children and adults with bipolar disorder
    Pilyoung Kim
    NIMH, Bethesda, MD, USA
    Am J Psychiatry 169:642-9. 2012
    ..The authors used functional MRI to compare amygdala activity during a face processing task in children and adults with bipolar disorder and in healthy comparison subjects...
  73. ncbi request reprint Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trials
    Jaskaran B Singh
    Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892, USA
    Bipolar Disord 8:696-709. 2006
    ..The aim of this review was to summarize the literature on controlled pharmacological trials that have been conducted in psychiatric conditions that commonly co-occur in bipolar disorder...
  74. pmc Bipolar disorder: candidate drug targets
    Carlos A Zarate
    Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, MD, USA
    Mt Sinai J Med 75:226-47. 2008
    ..Intracellular pathways and targets worthy of further study include glycogen synthase kinase-3 protein, protein kinase C, and the arachidonic acid cascade...
  75. ncbi request reprint Combination treatment in bipolar disorder: a review of controlled trials
    Carlos A Zarate
    The Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
    Bipolar Disord 5:217-25. 2003
    ..This article reviews the available published data from controlled, blinded studies regarding combination treatments in the different treatment phases of bipolar disorder...
  76. ncbi request reprint Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients
    Carlos A Zarate
    Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA
    Am J Psychiatry 161:169-71. 2004
    ..The goal of this study was to determine the benefits of the continued use of a typical antipsychotic agent following remission from an acute manic episode...
  77. pmc Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression
    Xiaochen Zhao
    Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA
    Br J Clin Pharmacol 74:304-14. 2012
    ....
  78. ncbi request reprint Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?
    Jennifer L Payne
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 1283, USA
    Biol Psychiatry 52:921-6. 2002
    ....
  79. pmc A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial
    Sanjay J Mathew
    Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Eur Neuropsychopharmacol 21:221-9. 2011
    ..The selective NK(1)R antagonist GR205171 had fewer adverse effects but was not significantly superior to placebo in the short-term treatment of chronic PTSD. (ClinicalTrials.gov Identifier: NCT 00211861, NCT 00383786)...
  80. ncbi request reprint Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profiling
    Rulun Zhou
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892 3711, USA
    Int J Neuropsychopharmacol 9:263-6. 2006
  81. ncbi request reprint Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometry
    Allison C Nugent
    Section on Neuroimaging in Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
    Neuroimage 30:485-97. 2006
    ....
  82. ncbi request reprint Neurobiology of bipolar disorder
    Andrew R Newberg
    National Institute of Mental Health, 10 Center Drive, MSC 1282, Building 10 CRC, Room 7 5545, Bethesda, MD 20892 1282, USA
    Expert Rev Neurother 8:93-110. 2008
    ....
  83. pmc Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
    Gerard Sanacora
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Nat Rev Drug Discov 7:426-37. 2008
    ..We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders...
  84. ncbi request reprint The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects
    Sungho Maeng
    Curr Psychiatry Rep 9:467-74. 2007
    ....
  85. ncbi request reprint Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study
    Mauricio Tohen
    Lilly Research Laboratories, IN 46285, USA
    Am J Psychiatry 160:1263-71. 2003
    ..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex...
  86. ncbi request reprint Olanzapine versus placebo in acute mania: treatment responses in subgroups
    Ross J Baldessarini
    International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    J Clin Psychopharmacol 23:370-6. 2003
    ..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania...
  87. ncbi request reprint Olanzapine versus divalproex in the treatment of acute mania
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, IN 46285, USA
    Am J Psychiatry 159:1011-7. 2002
    ..The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial...
  88. ncbi request reprint The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence
    Mauricio Tohen
    Lilly Research Laboratories, Brougher Building, 525 South Meridian, Indianapolis, IN 46225, USA
    Am J Psychiatry 160:2099-107. 2003
    ..Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset following first hospitalization for mania...
  89. ncbi request reprint Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine
    Jaskaran Singh
    Psychopharmacology (Berl) 173:227-8. 2004
  90. ncbi request reprint A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression
    Susan L McElroy
    Psychopharmacology Research Program, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
    J Clin Psychiatry 65:204-10. 2004
    ..Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study. We describe the results of a 52-week, open-label continuation of that trial...
  91. ncbi request reprint Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
    ..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone...
  92. ncbi request reprint Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial
    Roy H Perlis
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 67:1747-53. 2006
    ..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes...
  93. ncbi request reprint Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy
    Mauricio Tohen
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Arch Gen Psychiatry 59:62-9. 2002
    ....
  94. pmc A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania
    Rodrigo Machado-Vieira
    Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, RS, Brazil
    J Clin Psychiatry 69:1237-45. 2008
    ..This study aimed to evaluate the efficacy and tolerability of the purinergic agents allopurinol and dipyridamole combined with lithium in bipolar mania...
  95. ncbi request reprint Overweight and obesity in bipolar disorders
    Po W Wang
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 2117, CA 94305 5723, USA
    J Psychiatr Res 40:762-4. 2006
  96. pmc Increased rate of non-right-handedness in patients with bipolar disorder
    Cecylia Nowakowska
    J Clin Psychiatry 69:866-7. 2008